Singh, Udai
Primary Appointment
Associate Professor, Medicine: Hematology and Oncology
Education
- BS, Zoology and Chemistry, Gorakhpur University
- MS, Zoology, Gorakhpur University
- PhD, , Banaras Hindu University
- Postdoc, , Morehouse School of Medicine
Contact Information
1300 Jefferson Park Avenue
7225 E MSB West Complex (7225E)
Charlottesville, VA 22908
Telephone: 434.924.1954
Fax: 434.297.4101
Email: us4br@virginia.edu
Research Interests
Dr. Singh research interests are focused on 1) developing innovative therapeutic approaches to suppress autoimmune diseases by chemokine and alternative medicine; 2) developing novel strategies to attenuate obesity and regulatory T cells (Tregs) expansion
Research Description
My primary research interest includes chemokines, autoimmune disease, immunotherapy and alternative medicine. I am working on various model of inflammation that includes inflammatory bowel disease (IBD) and interstitial cystitis (IC). The causes and pathogenesis of these diseases in human remain unknown. We have shown that chemokine treatment abrogates both IBD and IC. We are also working on plant derived compound (Resveratrol) that protects against IBD by inducing myeloid derived suppressor cells (MDSCs), down regulating mucosal and systemic effectors CXCR3 expressing CD4 T-cells. This work will contribute to a better understanding of autoimmune disease pathogenesis and the development of inflammation therapeutics in general.
I am also working on the pathogenesis of obesity, which has become a major global health problem. We have shown that T-cell homeostasis expansion, macrophage polarization, and significant downregulation of differentially expressed miRs (miR-10a, miR-125b, miR-1247) in peripheral adipose tissue of mice fed in high fat diet as compared to normal diet. MiRs play a key role in facilitating the crosstalk between adipocytes, T-cells and macrophages during obesity. Therefore, understanding the novel links with miRs regulation, obesity, T-cell expansion, and macrophage function, which together contribute many pathophysiological effects on obesity. My current interest is to continue working on therapeutics by using regulatory T cells (Trges) in both mice model and clinical patients of diabetes. We will expand and functionally characterize these Tregs for both mice and clinical use.